Bicycle Therapeutics plc
BCYC
$7.12
$0.020.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.92M | 9.98M | 3.71M | 2.68M | 9.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.92M | 9.98M | 3.71M | 2.68M | 9.36M |
| Cost of Revenue | 71.03M | 57.27M | -60.82M | 45.65M | 40.06M |
| Gross Profit | -68.11M | -47.29M | 68.24M | -42.97M | -30.70M |
| SG&A Expenses | 18.49M | 22.91M | 15.30M | 20.87M | 15.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.52M | 80.18M | 71.37M | 66.52M | 56.01M |
| Operating Income | -86.60M | -70.20M | -67.66M | -63.85M | -46.65M |
| Income Before Tax | -79.18M | -61.84M | -52.94M | -54.25M | -39.70M |
| Income Tax Expenses | -231.00K | -1.09M | -1.08M | -3.45M | 115.00K |
| Earnings from Continuing Operations | -78.95M | -60.75M | -51.85M | -50.80M | -39.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.95M | -60.75M | -51.85M | -50.80M | -39.81M |
| EBIT | -86.60M | -70.20M | -67.66M | -63.85M | -46.65M |
| EBITDA | -84.91M | -68.57M | -65.96M | -61.67M | -45.01M |
| EPS Basic | -1.14 | -0.88 | -0.75 | -0.74 | -0.77 |
| Normalized Basic EPS | -0.71 | -0.56 | -0.52 | -0.48 | -0.48 |
| EPS Diluted | -1.14 | -0.88 | -0.75 | -0.74 | -0.77 |
| Normalized Diluted EPS | -0.71 | -0.56 | -0.52 | -0.48 | -0.48 |
| Average Basic Shares Outstanding | 69.25M | 69.20M | 69.05M | 68.99M | 51.99M |
| Average Diluted Shares Outstanding | 69.25M | 69.20M | 69.05M | 68.99M | 51.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |